These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33306631)

  • 21. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis.
    Filippi L; Di Costanzo GG; D'Agostini A; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Nucl Med Commun; 2018 Sep; 39(9):845-852. PubMed ID: 29901488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?
    Elsayed M; Cheng B; Xing M; Sethi I; Brandon D; Schuster DM; Bercu Z; Galt J; Barron B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):254-260. PubMed ID: 33000319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 24. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma.
    Aujay G; Debordeaux F; Blanc JF; Lapuyade B; Papadopoulos P; Bordenave L; Trillaud H; Pinaquy JB
    Nucl Med Commun; 2021 Jun; 42(6):633-638. PubMed ID: 33660694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
    Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
    Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer.
    Karahan Şen NP; Alataş Ö; Gülcü A; Özdoğan Ö; Derebek E; Çapa Kaya G
    Nucl Med Commun; 2022 Jul; 43(7):807-814. PubMed ID: 35506284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.
    Hyun SH; Eo JS; Lee JW; Choi JY; Lee KH; Na SJ; Hong IK; Oh JK; Chung YA; Song BI; Kim TS; Kim KS; Moon DH; Yun M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1638-45. PubMed ID: 26936852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging Predictors of Elevated Lung Shunt Fraction in Patients Being Considered for Yttrium-90 Radioembolization.
    Olorunsola OG; Kohi MP; Behr SC; Kolli PK; Taylor AG; Tong RT; LaBerge JM; Kerlan RK; Fidelman N
    J Vasc Interv Radiol; 2015 Oct; 26(10):1472-8. PubMed ID: 26296737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
    Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma.
    Li Q; Wang X; Li D; Liu Y; Liu K; Liang J; Sun J; Jiang Q; Li J; Liu Z; Gong J; Xiang L; Jia Z; Chen Z; Cao M; Jiang Y
    J Vis Exp; 2024 May; (207):. PubMed ID: 38856215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma.
    Sun M; Zhang G; Guo J; Hao S; Wang Z; Fan G
    Nucl Med Commun; 2018 Jun; 39(6):564-571. PubMed ID: 29634658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
    Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.